KN-92 is an inactive analog of the CaM kinase II inhibitor KN-93. KN-92 is intended to be used as a control compound in studies designed to elucidate the antagonist activities of KN-93. KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent kinase II (CaMKII), competitively blocking CaM binding to the kinase (Ki = 370 nM). KN-93 inhibits histamine-induced aminopyrine uptake in parietal cells (IC50 = 300 nM).
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
KN-93 inhibits androgen receptor activity and induces cell death irrespective of p53 and Akt status in prostate cancer.
Rokhlin OW, et al. Cancer Biol Ther. 2010 Feb;9(3):224-35. PMID: 20023417.
KN-93, a specific inhibitor of CaMKII inhibits human hepatic stellate cell proliferation in vitro.
An P, et al. World J Gastroenterol. 2007 Mar 7;13(9):1445-8. PMID: 17457979.
CaMKII-independent effects of KN93 and its inactive analog KN92: reversible inhibition of L-type calcium channels.
Gao L, et al. Biochem Biophys Res Commun. 2006 Jul 14;345(4):1606-10. PMID: 16730662.
|Related CaMK Products|
STO-609 acetate is a cell-permeable inhibitor of calcium/calmodulin-dependent kinase kinases (CaMKK) isoforms CaMKKα and CaMKKβ with Ki of 80 and 15 ng/ml, respectively.
KN 93 is a caM kinase II inhibitor; also K + channel blocker (K V).
KN-92 is an inactive analog of the CaM kinase II inhibitor KN-93.
KN-62 is a selective, cell permeable inhibitor of calcium/calmodulin-dependent kinase II (CaMKII; IC50 = 900 nM).
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.